Effectiveness of the Open Screening Programs in Recruiting Subjects to Prodromal and Mild Alzheimer’s Disease Clinical Trials - 21/11/24

Doi : 10.14283/jpad.2020.15 
Daniel Wójcik 1, 2, , K. Szczechowiak 1, M. Zboch 1, M. Pikala 3
1 Wroclaw Alzheimer’s Center — Wroclaw, Wroclaw, Poland 
2 Division of Quality Services, Procedures and Medical Standards, Medical University in Lodz, Lodz, Poland 
3 Department of Epidemiology and Biostatistics, the Chair of Social and Preventive Medicine of the Medical University of Lodz, Lodz, Poland 

a danielwojcik82@gmail.com

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Background and Objectives

Due to the lack of scientific data comparing the success and cost-effectiveness of trial recruiting strategies, the main goal of this paper is to present our results and experiences in recruiting participants to prodromal and mild AD clinical trials from an open-access screening program.

Design

The screening procedure includes the interview, and combined tests administration conducted by experienced neuropsychologist: Mini-Mental State Examination (MMSE) and Auditory-Verbal Learning Test (AVLT). The clinical evaluation was based on test scores, patient and/or caregiver interview, and the health questionnaire.

Settings and Participants

The open-access screening program was conducted in Wroclaw Alzheimer’s Center for 18 months (2018–2019). We invited individuals age 50 or older with the caregivers. The total number of subjects was 730 (N=730).

Measurements and Results: Due to our research, the detection rates in the screened population were 0,7% for severe dementia, 4,1% for moderate dementia, 18,6% for mild dementia, and 28,9% for mild cognitive impairment (MCI). From 347 individuals classified in our open-access screening programs as MCI or mild dementia patients, as many as 248 patients were screened in Alzheimer’s disease clinical trials, which is 71,47%. Moreover, 63 from 347 individuals selected from our program as MCI or mild dementia patients were randomized into the clinical trials, which is 18,16%. Furthermore, 63 from total 730 (8,6%) patients were randomized in clinical trials

Conclusions

Open-access screening programs can improve detection of MCI and dementia in society, help to distinguish demented from non-demented elderly, and improve recruitment of prodromal AD patients who would probably not have come to the memory clinic otherwise.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Alzheimer’s disease, mild cognitive impairment, dementia, screening, randomized controlled trial


Mappa


 Conflicts of interest: There are no conflict of interest.
 Ethical standards: This work was conducted in accordance with the principles set fourth by the Declaration of Helsinki. All volunteers gave written iformed consent before participating.


© 2020  THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 7 - N° 4

P. 251-255 - Settembre 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • The Alzheimer’s Prevention Registry: A Large Internet-Based Participant Recruitment Registry to Accelerate Referrals to Alzheimer’s-Focused Studies
  • Jessica B. Langbaum, N. High, J. Nichols, C. Kettenhoven, E.M. Reiman, P.N. Tariot
| Articolo seguente Articolo seguente
  • PTI-125 Reduces Biomarkers of Alzheimer’s Disease in Patients
  • H.-Y. Wang, Z. Pei, K.-C. Lee, E. Lopez-Brignoni, B. Nikolov, C.A. Crowley, M.R. Marsman, R. Barbier, N. Friedmann, Lindsay H. Burns

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.